{"id":158991,"date":"2010-01-09T15:28:27","date_gmt":"2010-01-09T20:28:27","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=57813"},"modified":"2010-01-09T15:28:27","modified_gmt":"2010-01-09T20:28:27","slug":"kineta-collects-942k","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/158991","title":{"rendered":"Kineta Collects $942K"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/finances\/\">Finances<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Kineta, a Seattle-based company developing treatments for viral infections and autoimmune diseases, has raised $942,000 in the form of equity, debt, and options from 25 investors, according to a regulatory <a href=\"http:\/\/www.sec.gov\/Archives\/edgar\/data\/1479365\/000147936510000001\/xslFormDX01\/primary_doc.xml\">filing<\/a>. The company pulled in a bigger sum in November, <a href=\"http:\/\/www.xconomy.com\/seattle\/2009\/11\/10\/seattles-kineta-rakes-in-half-of-13m-federal-contract-to-uw-for-vaccine-boosters\/\">garnering about half of a $13 million grant from the National Institutes of Health<\/a>, in which it will seek to develop new adjuvant compounds that boost the effectiveness of vaccines. &#8220;This is evidence that our business model is working,&#8221; says Meg O&#8217;Connor, Kineta&#8217;s director of investor relations.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/01\/09\/kineta-collects-942k\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Kineta%20Collects%20$942K%20http:\/\/xconomy.com\/?p=57813\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/seattle\/2010\/01\/09\/kineta-collects-942k\/&#038;t=Kineta%20Collects%20$942K\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/seattle\/2010\/01\/09\/kineta-collects-942k\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Kineta+Collects+%24942K&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fseattle%2F2010%2F01%2F09%2Fkineta-collects-942k%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=9ad63559e98560f3c56c77de4208c85d&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=9ad63559e98560f3c56c77de4208c85d&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/9NzhYp_5xz-I4C6V-K9GVIZQGeo\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/9NzhYp_5xz-I4C6V-K9GVIZQGeo\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/9NzhYp_5xz-I4C6V-K9GVIZQGeo\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/9NzhYp_5xz-I4C6V-K9GVIZQGeo\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/EguFy545eEo\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, deals, Finances Luke Timmerman wrote: Kineta, a Seattle-based company developing treatments for viral infections and autoimmune diseases, has raised $942,000 in the form of equity, debt, and options from 25 investors, according to a regulatory filing. The company pulled in a bigger sum in November, garnering about half of a $13 million grant from [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-158991","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/158991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=158991"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/158991\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=158991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=158991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=158991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}